Pre-employment drug test cost by panel, method, and regulatory context
Drug screening pricing is driven by panel type, method (urine, hair, oral fluid), and whether DOT chain-of-custody applies. Here is the honest price reference and the state-by-state regulatory landscape.
Pricing is panel-driven and process-driven
The two factors that drive pre-employment drug test pricing are the panel (what is screened for) and the process (collection method, chain-of-custody, Medical Review Officer review). The vendor matters less than employers often assume; pricing among the major occupational health networks (Quest Diagnostics, Labcorp, Concentra, US HealthWorks, and the dozens of regional providers) is roughly comparable on like-for-like packages, with volume contracts compressing the per-test rate for higher-hire-volume employers.
The most common pre-employment package is a 5-panel urine test ($30 to $50 per hire). It screens for the five drug classes most commonly tested (amphetamines, cocaine, opiates, PCP, THC). A 10-panel adds barbiturates, benzodiazepines, methadone, methaqualone, and propoxyphene for an extra $15 to $30. Custom panels adding synthetic opioids (notably fentanyl) or expanded benzodiazepines add another $10 to $25.
DOT-regulated tests follow a federally mandated 5-drug schedule with specific cutoff levels and chain-of-custody requirements. The DOT chain-of-custody process and the required Medical Review Officer review add modest cost (typically $40 to $70 per test versus $30 to $50 for an equivalent non-regulated test). This is the price of regulator-defensible results, not a vendor markup.
Hair-based testing is the longest-detection-window option (approximately 90 days versus 1 to 3 days for urine). It costs more per test ($150 to $300) and is typically reserved for roles where the longer detection window is operationally important: certain executive positions, some federally regulated roles, and positions in industries with elevated substance-related liability. The trade-off versus urine is straightforward: longer detection, higher cost, longer turnaround.
Drug test cost by type and panel
| Test type | Detection window | Typical price | Turnaround | When used |
|---|---|---|---|---|
| 5-panel urine | 1 to 3 days | $30 to $50 | 1 to 2 days | Most common pre-employment baseline |
| 10-panel urine | 1 to 3 days | $45 to $80 | 1 to 2 days | Expanded class coverage |
| 5-panel + fentanyl + expanded opioids | 1 to 3 days | $50 to $90 | 1 to 2 days | Healthcare, EMS, certain industrial |
| DOT 5-panel (regulated) | 1 to 3 days | $40 to $70 | 1 to 5 days | FMCSA, FAA, FRA, USCG, PHMSA roles |
| Oral fluid (saliva) | 1 to 3 days | $30 to $60 | Instant rapid or 1 day lab | Random testing, less invasive |
| Hair test (5-panel) | Up to 90 days | $150 to $250 | 3 to 7 days | Executive, regulated, sensitive roles |
| Hair test (10-panel) | Up to 90 days | $200 to $300 | 3 to 7 days | Deep-history screening |
| Breath alcohol | Few hours | $25 to $50 | Instant | DOT pre-employment, post-accident |
| EtG / EtS urine (alcohol) | Up to 80 hrs | $60 to $120 | 1 to 3 days | Treatment programs, certain regulated |
| MRO review fee | n/a | $5 to $20 per case | 1 to 5 days when triggered | Required for all non-negative results |
Pricing reflects typical 2026 occupational health network rates (Quest Diagnostics, Labcorp, Concentra). Collection-site visit fees are sometimes bundled, sometimes separate (typically $5 to $15 extra). Detection windows from SAMHSA and lab-published guidance.
State-by-state marijuana testing restrictions
As of 2026, at least 10 states and Washington DC have laws restricting employer pre-employment marijuana testing for most non-safety-sensitive roles. The laws vary substantially in scope. Some prohibit only off-duty use as a basis for adverse action; others prohibit pre-employment THC testing entirely for non-safety-sensitive roles. The fastest-growing pattern is restriction on pre-employment THC testing combined with continued permission for reasonable-suspicion and post-accident testing.
States with significant restrictions in 2026 include California, Connecticut, Montana, Nevada, New Jersey, New York, Rhode Island, Washington, Washington DC, and others. Each year more states join. The pattern usually leaves DOT-regulated testing unchanged (federal preemption); for non-regulated positions, employers operating in covered states typically either drop THC from the pre-employment panel or restrict testing to clearly safety-sensitive roles.
The practical implication for cost: a national employer with a single pre-employment policy needs either a state-specific panel (dropping THC where required) or a single panel that omits THC nationwide. Many employers have moved to the latter for non-safety-sensitive roles. The cost saving from dropping THC is small ($3 to $8 per test); the bigger benefit is candidate-experience and the elimination of state-by-state policy complexity.
DOT-regulated drug testing specifics
Federally regulated industries operate under 49 CFR Part 40, the Department of Transportation drug and alcohol testing procedures. The covered modes are commercial trucking (FMCSA), aviation (FAA), railroad (FRA), maritime (USCG), pipeline (PHMSA), and transit (FTA). Each agency has industry-specific implementation rules but all follow the Part 40 procedures for testing.
The DOT 5-panel schedule covers marijuana, cocaine, amphetamines (including methamphetamine and MDMA), opioids (including the synthetic opioids hydrocodone, hydromorphone, oxycodone, oxymorphone), and PCP. Cutoff levels are federally specified. Chain of custody must follow Part 40 protocols, including specific collection-site requirements, specimen handling, laboratory testing by a HHS-certified lab, and Medical Review Officer review before any non-negative result is reported to the employer.
The DOT process is more rigorous than non-regulated testing, which is why per-test cost is slightly higher ($40 to $70 versus $30 to $50). For DOT-regulated employers (any trucking company employing CDL drivers, for instance), the regulated process is not optional and the cost is part of the regulatory operating environment. Marijuana state laws do not override DOT regulations; federal law continues to require THC testing for DOT-regulated roles regardless of state legalisation.